Xiamen Humanity Hospital
The average astrocytoma treatment cost in China typically includes surgical options like craniotomy, which runs from $22,500 to $44,000. For targeted non-invasive care, stereotaxic radiosurgery ranges from $8,500 to $15,800. Total expenses depend on the tumor grade, hospital classification, and required chemotherapy cycles. Patients can achieve 65% to 85% savings compared to the US. Top medical destinations include Beijing, Shanghai, and Guangzhou.
Typical Astrocytoma Treatment Costs in China
Bookimed Expert Insight: For complex neuro-oncology cases, tertiary hospitals like Xiamen Humanity Hospital offer advanced infrastructure including 47 specialized departments. Patients seeking cutting-edge protocols may benefit from clinics accredited for Phase I–IV drug trials. For high-precision radiotherapy, experts like Dr. Liu Shi Xin provide specialized experience in VMAT and SBRT technologies. These high-volume centers manage over 1,000,000 patients annually, balancing innovative clinical trials with established surgical care.
| China | Turkey | Austria | |
| Stereotaxic radiosurgery | from $8,500 | from $4,500 | from $17,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Craniotomy | from $22,500 | from $5,650 | from $20,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Halcyon | - | from $5,400 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Astrocytoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Astrocytoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Astrocytoma treatment journey.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.